New HPV test aims to bring screening to more people

NCT ID NCT06434337

Recruiting now Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new point-of-care diagnostic test for HPV, called the Rice HPV test, to see if it works as well as standard tests. Researchers at MD Anderson Cancer Center will enroll 600 people with a cervix aged 21 or older. The goal is to develop a test that requires less equipment and is more accessible, especially for communities with limited resources.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rice HPV test (point-of-care diagnostic test)
What this could lead to: If successful, this could lead to a simpler, more accessible HPV test that requires less equipment, making screening easier in underserved areas.
What could go wrong: This is an early evaluation study. The new test may not match the accuracy of standard tests, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN PAPILLOMAVIRUS

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.